Recombinant HRV 3C Protease

Temporarily not available outside of China.
Recombinant human rhinovirus (HRV 3C) protease
The recombinant human rhinovirus (HRV 3C) protease is used to remove fusion tags from proteins with the HRV 3C cleavage sequence (PreScission Site): Leu-Glu-Val-Leu-Phe-Gln↓Gly-Pro or LEVLFQ↓GP.

The recombinant HRV 3C protease is a fusion protein of 22-kDa size, with a his tag. The enzyme retains high activity at 4℃, and can cleave the target protein in solution, in dialysis or on column.
Product Advantages
  1. High specificity: recognizes sequence Leu-Glu-Val-Leu-Phe-Gln-↓-Gly-Pro and cleaves after the glutamine residue.
  2. Retain high activity at 4℃: cleavage at low temperature preventing instability of target protein at high temperature.
  3. Easy removal: His-tagged protease can be easily removed after cleavage using a variety of solid supports with immobilized metal chelates.
  4. Lyophilized form: increases the stability and shelf life during storage and shipping, and decreases the shipping cost.
  5. Flexible: HRV 3C protease can cleave the target protein in solution, in dialysis or on column.
  6. Cost effective (cost saving): >50% cost saving, lower price, double size.
Product Components
Component Unit Note
Recombinant HRV 3C Protease 2000 U lyophilized from 50mM Tris, 150mM NaCl, 1mM EDTA, 1mM DTT, 0.04% Tween20, 8% trehalose, 8% mannitol
Cleavage Control Protein 100 μg lyophilized from sterile PBS , pH 7.4
10X HRV 3C Cleavage Buffer 5 mL 1.5 M NaCl , 0.5 M Tris-HCl , pH 7.5
Activity Definition: One unit of HRV 3C Protease is defined as the amount of enzyme that will cleave > 95% of 100μg Cleavage Control Protein in 150 mM NaCl, 50 mM Tris-HCl, pH 7.5 at 4℃ in 17h.
Storage: HRV 3C protease at –20℃; cleavage control protein and cleavage buffer at –20℃ or 4℃.
Reconstitution: Resuspend the enzyme powder with sterile water. Keep reconstituted enzyme at -20℃ in aliquots.

Experimental outline
Purify fusion protein
Digest with HRV 3C Protease containing His-Tag
Mix with Ni-NTA His Bind Resin
Cleaved target protein flows through
N-terminal His-Tag and HRV 3C Protease remain on resin
HRV 3C protease digest condition:
Temperature: 4℃
Incubation time: 16 hours or overnight
Enzyme amount: For most applications, 1:100–1:25 enzyme-to-substrate ratio (unit/μg)
Small scale optimization: Due to various properties of fusion proteins, the ratio of HRV 3C protease: target protein, temperature, incubation time is recommended to be optimized for practical application.
The following protocol is a simple example to estimate the appropriate amount of the enzyme.
  1. Combine 100μg fusion protein, 10μL 10×HRV 3C protease Cleavage Buffer, HRV 3C protease of different volumes and sterile water to make a 100μL total reaction volume. A control sample without HRV 3C protease should be included to detect a possible unspecific cleavage either by autolysis or by proteolytic contaminations of the fusion protein.
    Component Volume (μL)
    enzyme volume (μL) X
    100μg control protein Y
    10X Cleavage buffer 10
    Sterile water 100-X-Y
  2. Incubate the reaction mixture at 4℃ for 16 hours or overnight.
  3. Take out 20μL sample and add 20μL 2×SDS-PAGE loading buffer for each treatment and store at -20℃ until SDS-PAGE analysis. If practical, take out aliquots at different time spots to optimize the incubation time.
  4. Determine and compare the extent of cleavage of the samples by SDS-PAGE analysis.
The protease: target protein ratio can reach 1:800 in our experiment, but we recommend excessive use of the high specificity protease(1:100~1:25) to insure enzymatic digest completely in different experiments.

If shorter incubation time is required, more amount of HRV 3C protease or higher temperature (RT) can be implemented.

When the cleavage conditions are optimized at a small scale, scale up the cleavage proportionally according to specific application requirement.

If IMAC Ni-charged resin is used after cleavage to remove the HRV 3C protease, the buffer of target protein should be exchanged into suitable buffers without EDTA or imidazole. Buffer exchange can be carried out by desalting or dialysis.
Fig. The control protein was cleaved by HRV 3C protease at 4℃ for 16 h.
Additional information
Molecular weight: ~22KDa on SDS-PAGE SDS-PAGE:
Purity: 98% by SDS-PAGE.
Quality control: The purity of each lot is determined by SDS-PAGE. and the activity is ensured by cleavage test with a recombinant fusion protein for each lot. The solution of HRV 3C protease is filtered through 0.22μm sterile filter before package.
Factors that influence HRV 3C activity
Depending on the buffers used and their chemical components, HRV 3C Protease cleavage efficiency may be affected. The following table shows the relative activity of HRV 3C Protease under various conditions.
Factor Reagent Concentration Relative Activity (%)
Salt  NaCl 0.8M 150
0.2M 110
2.5~3M 200
ZnCl2 0.2mM 0
Na2SO4 0.8M 1570~7200
Protease inhibitor  EDTA 50mM 100
EGTA 50mM 100
Egg White cystatin 8μM 100
E-64 100μM 100
Iodoacetamide 1.0±0.1mM 50
Pepstatin 20μM 100
Aprotinin 15μM 100
Benzamidine 50mM 100
Leupeptin 0.75±0.05mM 50
PMSF 8.0±0.2mM 50
TLCK >1.0mM 50
Denaturant  Urea 3M 0
2M 0
1M 40
Guanadine  3M 0
2M 0
1M 0
Reductant DTT 1mM 100
Detergent  Triton X-100 0.10% >100
1% 100
Tween 20 0.10% >100
1% 100
Nonidet P-40  0.10% >100
1% 100
Anion(Na salt)  F- 0.2M 250
0.4M 470
Cl- 0.2M 110
0.4M 130
0.8M 150
Br- 0.2M 90
0.4M 85
0.8M 81
I- 0.2M 81
0.4M 63
0.8M 54
CH3CO2- 0.2M 150
0.4M 181
0.8M 338
SO32- 0.2M 122
0.4M 220
0.8M 365
SO42- 0.2M 252
0.4M 680
0.8M 1570
1M 2200
Co-solvent  Acetonitrile 10% 48
DMSO 10% 74
Isopropanol 10% 74
Methanol 10% 91
Glycerol 10% 114
Etylene glycol 10% 95
PEG-3400 10% 90
Sorbitol 10% 120
Sucrose 10% 112
Elute buffer Imidazole 20~250mM 100
Troubleshooting guide
Problem Probable cause Solution
Incomplete cleavage  Suboptimal HRV 3C Protease to fusion protein ratio Confirm the amount of fusion protein in the digestion. Adjust the amount of HRV 3C Protease added to at least 10 U/mg fusion protein.
Insufficient incubation period Increase reaction time.
HRV 3C Protease recognition site not present or has been altered during the course of cloning. Verify presence of optimal HRV 3C Protease cleavage sequence.
HRV 3C Protease recognition site is not accessible. Reversibly denature protein with non-ionic detergents, denaturants .
HRV 3C Protease inhibitors present Dialyze the fusion protein against Cleavage Buffer before cleaving with HRV 3C Protease.
On-column cleavage less than optimal. Increase HRV 3C Protease concentration.
Perform cleavage in solution or dialysis.
HRV 3C Protease contamination after purification with Ni-NTA HisBind resin Ni-NTA His•Bind Resin was
saturated with His•Tag fusion protein or fusion tag. Removal of HRV 3C Protease by the resin was incomplete.
Increase amount of Ni-NTA His•Bind Resin or decrease amount of extract loaded on Ni-NTA His•Bind Resin.
Pass sample over freshly prepared or regenerated Ni-NTA His•Bind Resin.
Multiple bands present on SDS-PAGE Gel following cleavage by HRV 3C Protease Similar secondary recognition sequences in protein of interest. Adjust reaction conditions to minimize exposure of secondary cleavage sites.
Proteolysis at secondary sites due to excess HRV 3C Protease Reduce HRV 3C Protease concentration.
Proteolysis in bacterial host Use protease-deficient strain (e.g., lon or ompT), such as E. coli BL21(DE3).
Background information
The catalytic activities of 3C protease have been found to be essential for generation of mature viral proteins and functional viral enzymes and thus for viral replication in the human rhinoviruses (HRVs) which are members of the picornavirus family and are the major causative agents of common cold. HRVs contain a single strand, positive-sense RNA genome which encodes a single viral polyprotein. This polyprotein precursor is further processed by two viral proteases designated 2A and 3C protease. It is believed that the 2A protease makes the first cleavage at its own N-terminus to separate the structural capsid proteins from the nonstructural ones, while the 3C protease processes most of the remaining sites.
Structure of HRV 3C protease Sequence comparison, structure and mutational analysis, and studies with classic protease inhibitors have all shown that HRV 3C protease contains an active site cysteine residue as the nucleophile. However, its overall structures are more like serine proteases rather than the typical cysteine proteases. For HRV 3C protease, the catalytic triad is composed of His-Glu-Cys and is positioned as seen in serine proteases. HRV 3C protease will fold into two anti-parallel six-stranded β-barrels and the site cleft is located at the junction of the two β-barrels domains.
Activity of HRV 3C protease In infected cells, HRV14 3C is able to process the polyprotein precursor at the scissile bonds formed between Gln-Gly, Gln-Ala, and Glu-Gly. However, in vitro studies have shown that this enzyme has a robust activity to cleave at the PreScission site (Leu-Glu-Val-Leu-Phe-Gln-↓-Gly-Pro) with high specificity. And the enzyme requires neither metal nor cofactors for activity. It has been demonstrated that the enzyme exhibits highest activity around neutral pH at temperatures ranging from 22 to 37℃, even retaining robust activity at 4℃.
Recombinant HRV 3C protease Recombinant HRV 3C protease encoded by human rhinovirus 14 is a highly purified recombinant protease with a His-tag or GST-tag produced in E.coli system which has the activity as same as the wild type. The protease is a ~20kDa single-chain protein containing approximately 182 amino acids cover the 1538-1717 region of HRV 14's Genome polyprotein (Accession #: P03303) with calculated isoelectric point 8.46.
  1. MG Cordingley, RB Register, PL Callahan. (1989) Cleavage of Small Peptides In Vitro by Human Rhinovirus 14 3C Protease Expressed in Escherichia coli. J. Virol. 63, 5037-5045
  2. Q May Wang, SH Chen. (2007) Human Rhinovirus 3C Protease as a Potential Target for the Development of Antiviral Agents. Current Protein and Peptide Science, 8:18-27
  3. DA Matthews, WW Smith, RA Ferre. (1994) Structure of Human Rhinovirus 3C Protease Reveals a Trypsin-like Polypeptide Fold, RNA-Binding Site, and Means for Cleaving Precursor Polyprotein. Cell, 77, 761-771.
  4. Q Wang, RB Johnson. Johnson. (2001) Activation of Human Rhinovirus-14 3C Protease. Virology 280, 80-86
  • AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B
    Johanns, M;Lai, YC;Hsu, MF;Jacobs, R;Vertommen, D;Van Sande, J;Dumont, JE;Woods, A;Carling, D;Hue, L;Viollet, B;Foretz, M;Rider, MH;
    Nat Commun
  • Direct interaction of the resistance to inhibitors of cholinesterase type 3 protein with the serotonin receptor type 3A intracellular domain
    Nishtala, SN;Mnatsakanyan, N;Pandhare, A;Leung, C;Jansen, M;
    J. Neurochem.
  • High-level expression and purification of the major house dust mite allergen Der p 2 in Escherichia coli
    Cao, T;Zhang, Z;Liu, ZG;Dou, X;Zhang, J;Zhang, W;Wu, B;Yu, ZD;Wei, Z;Yu, B;
    Protein Expr. Purif.
  • Production of Chemokine/Chemokine Receptor Complexes for Structural Biophysical Studies
    Gustavsson, M;Zheng, Y;Handel, TM;
    Meth. Enzymol.
  • Purification of a polyclonal antibody against CD147 for ELISA using antigen-immunoaffinity chromatography
  • Identification of quinone analogues as potential inhibitors of picornavirus 3C protease in vitro
    Jung, E;Lee, J;Kim, H;Ryu, C;Lee, K;Kim, M;Lee, C;Go, Y;
    Bioorganic & Medicinal Chemistry Letters
  • Rhinovirus 3C protease suppresses apoptosis and triggers caspase-independent cell death
    Lötzerich, M;Roulin, PS;Boucke, K;Witte, R;Georgiev, O;Greber, UF;
    Cell Death Dis
  • The intrinsically disordered C-terminal F domain of the ecdysteroid receptor from Aedes aegypti exhibits metal ion-binding ability
    Więch, A;Rowińska-Żyrek, M;Wątły, J;Czarnota, A;Hołubowicz, R;Szewczuk, Z;Ożyhar, A;Orłowski, M;
    J. Steroid Biochem. Mol. Biol.
Add to Cart Successfully Add to Cart Failed Shopping cart is being updated, please wait U.S.A.